LXN Corporation
This article was originally published in The Gray Sheet
Executive Summary
Maker of the Duet glucose control monitoring system raises $10.2 mil. in private financing. "The additional capital strengthens and solidifies the company's financial position as it continues to grow its customer base in the healthcare professional market and prepares for launch into the consumer market," LXN says. The device was cleared via 510(k) in October 1997. Venture capital firm MPM Asset Management was lead investor for the financing
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.